Experimental infection of cats with Tritrichomonas foetus.
OBJECTIVE
To determine whether infection with Tritrichomonas foetus causes diarrhea in specific-pathogen-free or Cryptosporidium coinfected cats.


METHODS
4 cats with subclinical cryptosporidiosis (group 1) and 4 specific-pathogen-free cats (group 2).


METHODS
Cats were infected orogastrically with an axenic culture of T. foetus isolated from a kitten with diarrhea. Direct microscopy and protozoal culture of feces, fecal character, serial colonic mucosal biopsy specimens, and response to treatment with nitazoxanide (NTZ; group 1) or prednisolone (groups 1 and 2) were assessed.


RESULTS
Infection with T. foetus persisted in all cats for the entire 203-day study and resulted in diarrhea that resolved after 7 weeks. Group-1 cats had an earlier onset, more severe diarrhea, and increased number of trichomonads on direct fecal examination, compared with group-2 cats. Use of NTZ eliminated shedding of T. foetus and Cryptosporidium oocysts, but diarrhea consisting of trichomonad-containing feces recurred when treatment was discontinued. Prednisolone did not have an effect on infection with T. foetus but resulted in reappearance of Cryptosporidium oocysts in the feces of 2 of 4 cats. During necropsy, T. foetus was isolated from contents of the ileum, cecum, and colon. Tritrichomonas foetus organisms and antigen were detected on surface epithelia and within superficial detritus of the cecal and colonic mucosa.


CONCLUSIONS
After experimental inoculation in cats, T. foetus organisms colonize the ileum, cecum, and colon, reside in close contact with the epithelium, and are associated with transient diarrhea that is exacerbated by coexisting cryptosporidiosis but not treatment with prednisolone.
Gookin
J L
JL
Department of Anatomy, Physiological Sciences and Radiology, College of Veterinary Medicine, North Carolina State University, Raleigh 27606, USA.
Levy
M G
MG
Law
J M
JM
Papich
M G
MG
Poore
M F
MF
Breitschwerdt
E B
EB
D000818:Animals; D000953:Antigens, Protozoan / Q000032:analysis; D000981:Antiprotozoal Agents / Q000008:administration & dosage / Q000627:therapeutic use; D002371:Cat Diseases / Q000188:drug therapy / Q000469:parasitology*; D002415:Cats; D003457:Cryptosporidiosis / Q000150:complications / Q000188:drug therapy / Q000662:veterinary; D003458:Cryptosporidium / Q000254:growth & development; D003967:Diarrhea / Q000188:drug therapy / Q000469:parasitology / Q000662:veterinary; D005243:Feces / Q000469:parasitology; D005260:Female; D007410:Intestinal Diseases / Q000188:drug therapy / Q000469:parasitology / Q000662:veterinary*; D007413:Intestinal Mucosa / Q000469:parasitology; D009574:Nitro Compounds; D010270:Parasite Egg Count / Q000662:veterinary; D011239:Prednisolone / Q000008:administration & dosage / Q000627:therapeutic use; D011528:Protozoan Infections / Q000150:complications / Q000188:drug therapy; D011529:Protozoan Infections, Animal; D013047:Specific Pathogen-Free Organisms; D013844:Thiazoles / Q000008:administration & dosage / Q000627:therapeutic use; D016835:Tritrichomonas foetus
D000953:Antigens, Protozoan; D000981:Antiprotozoal Agents; D009574:Nitro Compounds; D013844:Thiazoles; D011239:Prednisolone; C041747:nitazoxanide